Neither takers nor makers: The Big-4 auditing firms as regulatory intermediaries
Accounting History · 2020-08 · 25 (3) · 349-374
DOI: 10.1177/1032373219875219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Accounting History, online erschienen am 30.10.2019. Verfasst von Lior Herman. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 101 Literaturangaben.
Abstract (Originalsprache)
What are regulatory intermediaries? What roles do regulatory intermediaries play? What is the basis of their regulatory capacity and authority? This article examines these questions by focusing on the Big-4 international audit firms in the context of harmonizing international financial reporting standards. I argue that regulatory intermediaries perform a variety of regulatory market failure correcting functions for both regulatory makers and takers. Intermediation is far from being secondary to the regulatory process, and intermediaries, particularly those of transnational nature, have a pivotal role. Furthermore, regulatory intermediaries, as exemplified in the case of the Big-4, continuously challenge the primacy of the state, and the division of labor and balance of power between regulatory actors. Regulatory entrepreneurship and activism, coupled with unique organizational model based on global networks of partnerships, have led to the ascension of the Big-4 to unprecedented regulatory and market powers.
Zitieren
APA
Herman, L. (2020). Neither takers nor makers: The Big-4 auditing firms as regulatory intermediaries. Accounting History, 25(3), 349-374. https://doi.org/10.1177/1032373219875219
Vancouver
Herman L. Neither takers nor makers: The Big-4 auditing firms as regulatory intermediaries. Accounting History. 2020;25(3):349-374. doi:10.1177/1032373219875219
BibTeX
@article{Herman2020,
author = {Herman, Lior},
title = {Neither takers nor makers: The Big-4 auditing firms as regulatory intermediaries},
journal = {Accounting History},
year = {2020},
volume = {25},
number = {3},
pages = {349--374},
doi = {10.1177/1032373219875219}
}
EUVIMED